S E Monroe

No ORCID on file · 5 papers in corpus
nonrandomized-trial 1997
Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray
Fertility and sterility ·doi:10.1016/s0015-0282(97)80071-4

OBJECTIVE: To determine if the GnRH antagonist (GnRH-a) Ganirelix (Syntex Research, Palo Alto, CA), administered by intranasal (IN) spray to normal women, is absorbed into the systemic circulation and suppresses LH secretion. DESIGN: A sin…

other 1995
Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis
American journal of obstetrics and gynecology ·doi:10.1016/0002-9378(95)90348-8

OBJECTIVE: Our purpose was to investigate the effects of nafarelin on bone turnover and mass (bone mineral density, in grams per square centimeter) in women with endometriosis. STUDY DESIGN: We monitored 22 young women with endometriosis d…

nonrandomized-trial 1990
Nafarelin: a new medical therapy for endometriosis
Progress in clinical and biological research
other 1985
Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin)
Fertility and sterility ·doi:10.1016/s0015-0282(16)48970-3

Administration of superactive agonistic analogs of gonadotropin-releasing hormone (GnRH) has been shown to induce a paradoxic and reversible suppression of gonadotropins, resulting in suppressed gonadal steroid concentrations. Because there…

nonrandomized-trial 1984
Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jcem-58-4-755

In eumenorrheic women with endometriosis and in oligo-amenorrheic women with polycystic ovarian disease (PCO), chronic administration of a long-acting GnRH agonist (GnRH-a) reduced the circulating concentrations of estrogens and androgens t…